Clinical Trial Update: A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) [Phase 2]

View source ↗

Summary

Phase II trial evaluating the combination of DZD9008 with AZD4205 in NSCLC patients with EGFR mutations who failed standard therapy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD4205
• DZD9008

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING